By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Paris, 8 December 2016- ABIVAX, an innovative biotechnology company targeting the immune system to eliminate viral disease, announced that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/A
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Castle Creek Pharmaceuticals, LLC, a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, announced completion of an exclusive license agreement for all U.S. rights to Arlevert
LOS ANGELES Wednesday AHF lauded the publication of clinical trial results in the journal Lancet which showed 100 percent efficacy in preventing Ebola virus infection among study participants who received an experimental vaccine in Sierra Leone and Guinea. Every year the world collectively spends almost $2 trillion on defense and only $36 billio
Humacyte, an innovator in biotechnology and regenerative medicine, announced today the initiation of a U.S. Phase II arterial bypass clinical trial of HUMACYL, its investigational human acellular vessel, to test the safety and efficacy as a lower extremity arterial bypass vessel in patients with peripheral arterial disease. The initiation of the Ph
Pharmaceutical company Lupin has received tentative approval from the United States Food and Drug Administration to market its cholesterol lowering Pitavastatin tablets in the American market. has received approval for Pitavastatin tablets in the strength of 1 milligram, 2 mg and 4 mg. Pitavastatin is a generic version of Kowa's Livalo tablets in t
This file photo taken on March 10, 2015, shows a woman getting vaccinated at a health center in Conakry, Guinea, during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus. China says its first domestically-developed Ebola vaccine is a major medical breakthrough as it passed the Phase-II clinical test and gains permission for
In 2016, many new and useful medications got FDA approval. My articles are syndicated worldwide, but I'm only listing English drug names so please ask your local pharmacist to translate the medication name for your country. So the FDA approved this injectable drug to help people who have been exposed from infected animals, contaimated animal produc
Gainers Marinus Pharmaceuticals Inc rose 29.3 percent to $1.080 in pre-market trading as the company disclosed that ganaxolone has received Orphan Drug designation for the treatment of Fragile X Syndrome. China Cord Blood Corp shares rose 16.1 percent to $6.35 in pre-market trading after Golden Meditech agreed to sell its equity interest in China C
By a News Reporter-Staff News Editor at Health& Medicine Week Acerus Pharmaceuticals Corporation announced the signing of an agreement granting the exclusive right to market NATESTO in South Korea to Hyundai Pharm Co., LTD., a South Korean pharmaceutical company. "Hyundai has a proven track record of success in launching products, building ne
By a News Reporter-Staff News Editor at Drug Week amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, announced the closing of a Series B financing round amounting to a total of EUR 6 million. The financing comes from a consortium of existing investors and shareholders headed by LBBW Venture Capital, with participat
Aurobindo Pharma has received US Food and Drug Administration's approval for two of its generic drugs, following which the company stocks gained positive traction. Aurobindo Pharma has received US Food and Drug Administration's approval for two of its generic drugs, following which the company stocks gained positive traction. Aurobindo Pharma Ltd i
COPENHAGEN, Denmark, December 29, 2016- Bavarian Nordic A/S today announced the initiation of a clinical trial combining its proprietary cancer immunotherapy candidate, CV301, with the anti-PD-1 drug, OPDIVO from Bristol-Myers Squibb. "We are pleased to announce the initiation of this study, which marks the entry for Bavarian Nordic into lung canc
BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of the first patient in a Phase I clinical trial of BGB-A317, an anti-PD-1 monoclonal antibody, in mainland Chinese patients with advanced solid tumors.. We are enthusiastic ab
Dec. 29 Shares of Chapel Hill drug developer Cempra plummeted 57 percent Thursday after the company reported that the Food and Drug Administration declined to approve its experimental antibiotic. The FDA also informed the company that, although it reserves comment on drug labeling pending further tests, the risk of liver damage to patients is suc
By a News Reporter-Staff News Editor at Energy Weekly News- Oxeia Biopharmaceuticals, Inc., a biotechnology company leading the industry in the development of first-in-class neurometabolic treatments for concussions and brain injury, announced that Christopher Nowinski, co-founder and CEO of the Concussion Legacy Foundation, has joined the compan
WASHINGTON, Dec. 30 The Food and Drug Administration published the following rule in the Federal Register:. A Rule by the Food and Drug Administration on 12/27/2016. Agencies: Food and Drug Administration.
Khang& Khang LLP announces that it is investigating claims against Amphastar Pharmaceuticals, Inc. concerning possible violations of federal securities laws. Amphastar announced that its company Armstrong Pharmaceuticals, Inc. received notice from the U.S. Food and Drug Administration, revealing to Armstrong that its New Drug Application for...
Incyte Corporation today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease. The U.S. Food and Drug Administration has granted ruxolitinib Breakthrough Therapy...
-Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the annual Biotech ShowcaseTM conference on January 11, 2017.
By a News Reporter-Staff News Editor at Health& Medicine Week Current study results on Radius Fracture have been published. According to news reporting from Anjo, Japan, by NewsRx journalists, research stated, "Ulnar styloid fractures are often associated with distal radius fractures. The news correspondents obtained a quote from the research fro
This week, Lupin received tentative approval for generic Giazo Tablets, Aurobindo Pharma got US FDA approval for 2 drugs and Glenmark Pharma gets USFDA approval for Tretinoin Capsules. Lupin receives tentative approval for generic Giazo Tablets Pharma Major Lupin Limited announced that it has received tentative approval for its Balasalazide Disodiu
By a News Reporter-Staff News Editor at Drug Week Pharmaceutical Product Development LLC has expanded its stability sample storage capacity and capabilities as part of its ongoing efforts to meet the growing needs of its biopharmaceutical clients. "The expansion of our stability chamber capabilities in Middleton is indicative of PPD's ongoing ef
The FDA approval of CERASORB Ortho FOAM is an extremely important milestone for us in the re-orientation of our U.S. business, which will open up a potential market worth more than$ 900 million, said Michael Schlenk, CEO of curasan AG. curasan Inc. was established in the Triangle in 2004 and was subsequently purchased by RIEMSER Inc., a dental supp
Attorney Advertising Bronstein, Gewirtz& Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Innocoll Holdings, plc. On December 29, 2016, Innocoll revealed that it had received a Refusal to File letter from the U.S. Food& Drug Administration regarding its New Drug Application for XARACOLL, a postsurgica